Last reviewed · How we verify
NCT06771479
A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine
Phase 1 trial testing MVA strain monkeypox attenuated live vaccine (low dose) in Monkeypox in 120 participants. Currently enrolling.
30 January 2026
Quick facts
| Lead sponsor | Shanghai Institute Of Biological Products |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 120 |
| Start date | 22 January 2025 |
| Primary completion | 30 January 2026 |
| Estimated completion | 30 May 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- MVA strain monkeypox attenuated live vaccine (low dose) — full drug profile →
- MVA strain monkeypox attenuated live vaccine (high dose) — full drug profile →
- Placebo
Conditions studied
- Monkeypox — all drugs for Monkeypox →
Sponsor
Shanghai Institute Of Biological Products
Who can join
18 and older, any sex, with Monkeypox. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, double blinded, controlled phase I clinical study. To evaluate the safety and immunogenicity of receiving two doses of MVA strain monkeypox attenuated live vaccine in individuals aged 18 years and above.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Monkeypox Virus: Epidemiology, Virology, Diagnosis, Vaccine, and Therapeutics.
Yan Y, Sun Y, Sun G, Niu C, et al · · 2026 · cited 2× · PMID 41488472 · DOI 10.1002/mco2.70525
Verify or expand the search:
- PubMed search for NCT06771479
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Monkeypox
Currently open trials in the same condition.
- NCT07377175 — Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses. · Phase 1 · recruiting
- NCT05745987 — Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT · Phase 4 · recruiting
- NCT06045923 — Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV · recruiting
Other Shanghai Institute Of Biological Products trials
Trials by the same sponsor.
- NCT07363837 — Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants · Phase 1, PHASE2 · not yet recruiting
- NCT07327398 — Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 2 · not yet recruiting
- NCT07253675 — Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo · Phase 2 · not yet recruiting
- NCT07302256 — A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 1 · recruiting
- NCT07205198 — A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects. · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06771479 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Institute Of Biological Products
- Last refreshed: 3 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06771479.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing